GlobalData on MSN2d
Exelixis and MSD to trial cancer therapies together in clinical collaboration
US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...
Zacks.com on MSN2d
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Exelixis, Merck Sign Zanzalintinib Development Collaboration
Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...
Pharmabiz2d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...